APUS Share Price Performance
Recent APUS News & Updates
No updates
Apimeds Pharmaceuticals US, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.13
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -54.9%
Apimeds Pharmaceuticals US, Inc. Competitors
About APUS
- Founded
- 2020
- Employees
- 2
- CEO
- WebsiteView website
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, a purified, pharmaceutical grade venom of the Apis mellifera, or honeybee for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Matawan, New Jersey.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 10.1%
- 1 Year: 17.7%
- Year to Date: 5.9%
In the last week, the market has fallen 2.7%, dragged down most by the Financials. In the last year, the market is actually up 18%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading